论文部分内容阅读
目的观察黄葵胶囊联合奥美沙坦酯治疗IgA肾病轻中度蛋白尿的临床疗效。方法 80例IgA肾病轻中度蛋白尿患者,随机分成对照组和实验组,各40例。对照组患者采用奥美沙坦酯治疗,实验组患者采用黄葵胶囊联合奥美沙坦酯治疗。比较两组患者的治疗效果。结果两组患者经过12周的治疗,对照组治疗总有效率为67.5%(27/40),实验组治疗总有效率为92.5%(37/40)。实验组临床治疗总有效率显著高于对照组,差异有统计学意义(P<0.05)。治疗期间两组患者均没有发生显著的不良反应。结论临床中在对IgA肾病轻中度蛋白尿进行治疗时,黄葵胶囊联合奥美沙坦酯治疗具有显著的临床疗效,而且安全可靠,具有临床推广价值。
Objective To observe the clinical efficacy of Huang Kui capsule combined with olmesartan medoxomil treating mild to moderate proteinuria in patients with IgA nephropathy. Methods 80 cases of IgA nephropathy with mild to moderate proteinuria were randomly divided into control group and experimental group, 40 cases in each. The patients in the control group were treated with olmesartan medoxomil, and the patients in the experimental group were treated with the Huang Kui capsule combined with olmesartan medoxomil. The treatment effect of two groups of patients was compared. Results After 12 weeks of treatment, the total effective rate of the control group was 67.5% (27/40). The total effective rate of the experimental group was 92.5% (37/40). The total effective rate of clinical trial in experimental group was significantly higher than that in control group, the difference was statistically significant (P <0.05). During treatment, no significant adverse reactions occurred in both groups. Conclusion In clinical treatment of IgA nephropathy mild to moderate proteinuria, Huang Kui capsule combined with olmesartan medoxomil treatment has a significant clinical effect, and safe and reliable, with clinical value.